Yaoyao Zou

Yaoyao Zou

Auto-generated profile, based on publicly available information

Yaoyao Zou

Department of Rheumatology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
YZYaoyao Zou
Yaoyao Zou
SXSiqi Xu
Siqi Xu
YXYoujun Xiao
Youjun Xiao
QQQian Qiu
Qian Qiu
MSMaohua Shi
Maohua Shi
HXHanshi Xu
Hanshi Xu
Fibroblast-like synoviocytes (FLSs) are critical to synovial aggression and joint destruction in rheumatoid arthritis (RA). The role of long noncoding RNAs (lncRNAs) in RA is largely unknown. Here, we identified a lncRNA, LERFS (lowly expressed in rheumatoid fibroblast-like synoviocytes), that negatively regulates the migration, invasion, and proliferation of FLSs through interaction with heterogeneous nuclear ribonucleoprotein Q (hnRNP Q). Under healthy conditions, by binding to the mRNA of RhoA, Rac1, and CDC42 — the small GTPase proteins that control the motility and proliferation of FLSs — the LERFS–hnRNP Q complex decreased the stability or translation of target mRNAs and downregulated their protein levels. But in RA FLSs, decreased LERFS levels induced a reduction of the LERFS–hnRNP Q complex, which reduced the binding of hnRNP Q to target mRNA and therefore increased the stability or translation of target mRNA. These findings suggest that a decrease in synovial LERFS may contribute to synovial aggression and joint destruction in RA and that targeting the lncRNA LERFS may have therapeutic potential in patients with RA.

27 March 2017 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
YZYaoyao Zou
Yaoyao Zou
SZShan Zeng
Shan Zeng
MHMingcheng Huang
Mingcheng Huang
QQQian Qiu
Qian Qiu
YXYoujun Xiao
Youjun Xiao
HXHanshi Xu
Hanshi Xu

1 November 2019 in International Immunopharmacology
Verified
Journal Article
Closed access
JWJingnan Wang
Jingnan Wang
RLRuiru Li
Ruiru Li
HLHaobo Lin
Haobo Lin
QQQian Qiu
Qian Qiu
MLMinxi Lao
Minxi Lao
YXYoujun Xiao
Youjun Xiao

31 August 2015 in Rheumatology
Verified
Journal Article
Open access
PDF file
YXYoujun Xiao
Youjun Xiao
LLLiuqin Liang
Liuqin Liang
MHMingcheng Huang
Mingcheng Huang
QQQian Qiu
Qian Qiu
SZShan Zeng
Shan Zeng
HXHanshi Xu
Hanshi Xu
Objective. To explore the roles of the bromodomain (Brd) and extra-terminal domain (BET) of chromatin adaptors in regulating synovial inflammation in RA. Methods. Fibroblast-like synoviocytes (FLSs) were isolated from synovial tissue from RA patients. A specific BET inhibitor, JQ1, and short hairpin RNA (shRNA) for Brd2 or Brd4 were used to evaluate the role of the BET Brd in inflammatory responses. Protein expression was measured by western blot or immunofluorescence staining. Nuclear factor kappa B (NF-κB) gene activity was detected by luciferase assay. The secretion and gene expression of cytokines and MMPs were evaluated by ELISA and real-time PCR, respectively. FLS proliferation was detected by BrdU incorporation. Results. Four Brd proteins, including Brd2, Brd3, Brd4 and Brdt, were expressed in FLSs from patients with RA and OA; however, the expression of Brd2 and Brd4 was increased in RA compared with that in OA. Treatment with JQ1, Brd2 shRNA or Brd4 shRNA decreased the production of pro-inflammatory cytokines (TNFα, IL-1β, IL-6 and IL-8), MMPs expression (MMP-1, MMP-3 and MMP-13) and proliferation by RA FLSs. BET inhibition downregulated TNFα-induced NF-κB–dependent transcription and expression of the NF-κB target genes. JQ1 suppressed the phosphorylation of IκB kinaseβ and IκBα, and nuclear translocation of p65. Intraperitoneal injection of JQ1 in mice with collagen-induced arthritis reduced synovial inflammation, joint destruction and serum levels of the anti-CII antibodies TNFα and IL-6. Conclusion. This study implicates BET Brds as important regulators of IκB kinase/NF-κB–mediated synovial inflammation of RA and identifies BET proteins as novel therapeutic targets in inflammatory arthritis.

24 October 2016 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
MHMingcheng Huang
Mingcheng Huang
SZShan Zeng
Shan Zeng
YZYaoyao Zou
Yaoyao Zou
MSMaohua Shi
Maohua Shi
QQQian Qiu
Qian Qiu
HXHanshi Xu
Hanshi Xu
Background and Purpose: There is increasing evidence indicating that bromodomain and extra‐terminal domain (BET) proteins play a critical role in the regulation of immune and inflammatory responses; however, their contribution to vascular inflammation has not yet been elucidated. In this study, we investigated the effect of inhibiting BET bromodomain on vascular inflammation and the underlying mechanisms.Experimental Approach: HUVECs were isolated from fresh umbilical cords. JQ1, a specific BET bromodomain inhibitor, and Brd shRNA were used to evaluate the regulation of the BET proteins in vascular inflammation. Leukocyte adhesion to HUVECs was measure by an adhesion assay. Western blot or immunohistochemical analysis was used to detect the protein expression. Real‐time PCR was used to evaluate mRNA expression. Leukocyte accumulation in vivo was determined by an acute lung inflammation model.Key Results: BET bromodomain inhibition suppressed the expression of adhesion molecules induced by TNF‐α‐ or LPS, including ICAM‐1, VCAM‐1 and E‐selectin, and inhibited leukocyte adhesion to activated HUVEC monolayers. Treatment with JQ1 also attenuated the LPS‐induced accumulation of leukocytes and expression of endothelial adhesion molecules in the acute lung inflammation model in vivo. Furthermore, BET bromodomain inhibition reduced the activity of p38 and JNK MAPKs and NF‐κB in TNF‐α‐stimulated HUVECs. TNF‐α‐induced NF‐κB activation was also blocked by inhibitors of p38 (SB203580) or JNK (SP600125).Conclusions and Implications: BET bromodomain is important for regulating endothelial inflammation. Strategies targeting endothelial BET bromodomain may provide a new therapeutic approach for controlling inflammatory‐related diseases.

15 January 2016 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
MLMinxi Lao
Minxi Lao
MSMaohua Shi
Maohua Shi
YZYaoyao Zou
Yaoyao Zou
MHMingcheng Huang
Mingcheng Huang
YYYujin Ye
Yujin Ye
XHXu Hanshi
Xu Hanshi
The aggressive phenotype displayed by fibroblast-like synoviocytes (FLSs) is a critical factor of cartilage destruction in rheumatoid arthritis (RA). Increased FLSs migration and subsequent degradation of the extracellular matrix are essential to the pathology of RA. Protein inhibitor of activated STAT (PIAS), whose family members include PIAS1, PIAS2 (PIASx), PIAS3, and PIAS4 (PIASy), play important roles in regulating various cellular events, such as cell survival, migration, and signal transduction in many cell types. However, whether PIAS proteins have a role in the pathogenesis of RA is unclear. In this study, we evaluated the role of PIAS proteins in FLSs migration, invasion, and matrix metalloproteinases (MMPs) expression in RA. We observed increased expression of PIAS3, but not PIAS1, PIAS2, or PIAS4, in FLSs and synovial tissues from patients with RA. We found that PIAS3 knockdown by short hairpin RNA reduced migration, invasion, and MMP-3, MMP-9, and MMP-13 expression in FLSs. In addition, we demonstrated that PIAS3 regulated lamellipodium formation during cell migration. To gain insight into molecular mechanisms, we evaluated the effect of PIAS3 knockdown on Rac1/PAK1 and JNK activation. Our results indicated that PIAS3-mediated SUMOylation of Rac1 controlled its activation and modulated the Rac1 downstream activity of PAK1 and JNK. Furthermore, inhibition of Rac1, PAK1, or JNK decreased migration and invasion of RA FLSs. Thus, our observations suggest that PIAS3 suppression may be protective against joint destruction in RA by regulating synoviocyte migration, invasion, and activation.